Dosing & Uses
AdultPediatric
Organ Dysfunction or Failure
Pending FDA approval for suspected organ dysfunction or failure in patients aged ≥12 years with necrotizing soft tissue infection (NSTI), in conjunction with surgical debridement, antibiotic therapy, and supportive care
Organ Dysfunction or Failure
Pending FDA approval for suspected organ dysfunction or failure in patients aged ≥12 years with necrotizing soft tissue infection (NSTI), in conjunction with surgical debridement, antibiotic therapy, and supportive care
Next:
Pharmacology
Mechanism of Action
Acts early in the host immune response by binding to the dimer interface of CD28 expressed on T-cells, thereby modulating acute inflammation that leads to systemic organ failure
This action avoids ongoing concerns about bacterial resistance and is active independent of the pathogen type
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
